<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?DTDIdentifier.IdentifierValue http://null/schema/dtds/document/fulltext/xcr/xocs-article.xsd?><?DTDIdentifier.IdentifierType schema?><?SourceDTD.DTDName xocs-article.xsd?><?SourceDTD.Version 1.0?><?ConverterInfo.XSLTName ftrr2jats.xsl?><?ConverterInfo.Version 1?><?origin publisher?><front><journal-meta><journal-id journal-id-type="nlm-ta">Antiviral Res</journal-id><journal-id journal-id-type="iso-abbrev">Antiviral Res</journal-id><journal-title-group><journal-title>Antiviral Research</journal-title></journal-title-group><issn pub-type="ppub">0166-3542</issn><issn pub-type="epub">1872-9096</issn><publisher><publisher-name>Elsevier B.V.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7132364</article-id><article-id pub-id-type="publisher-id">S0166-3542(20)30114-5</article-id><article-id pub-id-type="doi">10.1016/j.antiviral.2020.104762</article-id><article-id pub-id-type="publisher-id">104762</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Of chloroquine and COVID-19</article-title></title-group><contrib-group><contrib contrib-type="author" id="au1"><name><surname>Touret</surname><given-names>Franck</given-names></name><email>franck.touret@univ-amu.fr</email></contrib><contrib contrib-type="author" id="au2"><name><surname>de Lamballerie</surname><given-names>Xavier</given-names></name><email>xavier.de-lamballerie@univ-amu.fr</email><xref rid="cor1" ref-type="corresp">&#x02217;</xref></contrib></contrib-group><aff id="aff1">Unit&#x000e9; des Virus Emergents, UVE: Aix Marseille Univ, IRD 190, INSERM 1207, IHU M&#x000e9;diterran&#x000e9;e Infection, 13005, Marseille, France</aff><author-notes><corresp id="cor1"><label>&#x02217;</label>Corresponding author. <email>xavier.de-lamballerie@univ-amu.fr</email></corresp></author-notes><pub-date pub-type="pmc-release"><day>5</day><month>3</month><year>2020</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.--><pub-date pub-type="ppub"><month>5</month><year>2020</year></pub-date><pub-date pub-type="epub"><day>5</day><month>3</month><year>2020</year></pub-date><volume>177</volume><fpage>104762</fpage><lpage>104762</lpage><history><date date-type="received"><day>29</day><month>2</month><year>2020</year></date><date date-type="rev-recd"><day>2</day><month>3</month><year>2020</year></date><date date-type="accepted"><day>2</day><month>3</month><year>2020</year></date></history><permissions><copyright-statement>&#x000a9; 2020 Elsevier B.V. All rights reserved.</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>Elsevier B.V.</copyright-holder><license><license-p>Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.</license-p></license></permissions><abstract id="abs0010"><p>Recent publications have brought attention to the possible benefit of chloroquine, a broadly used antimalarial drug, in the treatment of patients infected by the novel emerged coronavirus (SARS-CoV-2). The scientific community should consider this information in light of previous experiments with chloroquine in the field of antiviral research.</p></abstract><abstract abstract-type="author-highlights" id="abs0015"><title>Highlights</title><p><list list-type="simple" id="ulist0010"><list-item id="u0010"><label>&#x02022;</label><p id="p0010">In vitro data suggest that chloroquine inhibits SARS Cov-2 replication.</p></list-item><list-item id="u0015"><label>&#x02022;</label><p id="p0015">In past research, chloroquine has shown <italic>in vitro</italic> activity against many different viruses, but no benefit in animal models.</p></list-item><list-item id="u0020"><label>&#x02022;</label><p id="p0020">Chloroquine has been proposed several times for the treatment of acute viral diseases in humans without success.</p></list-item><list-item id="u0025"><label>&#x02022;</label><p id="p0025">The outcomes of some current clinical trials of chloroquine in China have been announced, without access to the data.</p></list-item><list-item id="u0030"><label>&#x02022;</label><p id="p0030">Peer review of the results and an independent assessment of the potential benefit for patients are essential.</p></list-item></list></p></abstract><kwd-group id="kwrds0010"><title>Keywords</title><kwd>SARS-CoV-2</kwd><kwd>COVID-19</kwd><kwd>2019-nCoV</kwd><kwd>Chloroquine</kwd><kwd>Antiviral</kwd></kwd-group></article-meta></front><body><p id="p0035">Recent publications have brought attention to the possible benefit of chloroquine, a broadly used antimalarial drug, in the treatment of patients infected by the novel emerged coronavirus (SARS-CoV-2) (<xref rid="bib3" ref-type="bibr">Colson et al., 2020</xref>; <xref rid="bib11" ref-type="bibr">Gao et al., 2020</xref>). The scientific community should consider this information in light of previous experiments with chloroquine in the field of antiviral research.</p><p id="p0040">The sulfate and phosphate salts of chloroquine have both been commercialised as antimalarial drugs. Hydroxychloroquine has also been used as an antimalarial, but in addition is now broadly used in autoimmune diseases such as lupus and rheumatoid arthritis. Of note, chloroquine and hydroxychloroquine are considered to be safe and side-effects are generally mild and transitory. However, the margin between the therapeutic and toxic dose is narrow and chloroquine poisoning has been associated with cardiovascular disorders that can be life-threatening (<xref rid="bib10" ref-type="bibr">Frisk-Holmberg et al., 1983</xref>). Chloroquine and hydroxychloroquine use should therefore be subject to strict rules, and self-treatment is not recommended.</p><p id="p0045">The <italic>in vitro</italic> antiviral activity of chloroquine has been identified since the late 1960's (<xref rid="bib13" ref-type="bibr">Inglot, 1969</xref>; <xref rid="bib19" ref-type="bibr">Miller and Lenard, 1981</xref>; <xref rid="bib26" ref-type="bibr">Shimizu et al., 1972</xref>) and the growth of many different viruses can be inhibited in cell culture by both chloroquine and hydroxychloroquine, including the SARS coronavirus (<xref rid="bib16" ref-type="bibr">Keyaerts et al., 2004</xref>). Some evidence for activity in mice has been found for a variety of viruses, including human coronavirus OC43 (<xref rid="bib15" ref-type="bibr">Keyaerts et al., 2009</xref>), enterovirus EV-A71 (<xref rid="bib27" ref-type="bibr">Tan et al., 2018</xref>), Zika virus (<xref rid="bib17" ref-type="bibr">Li et al., 2017</xref>) and influenza A H5N1 (<xref rid="bib31" ref-type="bibr">Yan et al., 2013</xref>). However, chloroquine did not prevent influenza infection in a randomized, double-blind, placebo-controlled clinical trial (<xref rid="bib21" ref-type="bibr">Paton et al., 2011</xref>), and had no effect on dengue-infecteds patient in a randomized controlled trial in Vietnam (<xref rid="bib28" ref-type="bibr">Tricou et al., 2010</xref>). Chloroquine was also active <italic>ex vivo</italic> but not <italic>in vivo</italic> in the case of ebolavirus in mice (<xref rid="bib8" ref-type="bibr">Dowall et al., 2015</xref>; <xref rid="bib9" ref-type="bibr">Falzarano et al., 2015</xref>), Nipah (<xref rid="bib20" ref-type="bibr">Pallister et al., 2009</xref>) and influenza virus (<xref rid="bib29" ref-type="bibr">Vigerust and McCullers, 2007</xref>) in ferrets.</p><p id="p0050">The case of chikungunya virus (CHIKV) is of specific interest: chloroquine showed promising antiviral activity <italic>in vitro</italic> (<xref rid="bib5" ref-type="bibr">Coombs et al., 1981</xref>; <xref rid="bib7" ref-type="bibr">Delogu and de Lamballerie, 2011</xref>), but was shown to enhance alphavirus replication in various animal models (<xref rid="bib18" ref-type="bibr">Maheshwari et al., 1991</xref>; <xref rid="bib23" ref-type="bibr">Roques et al., 2018</xref>; <xref rid="bib25" ref-type="bibr">Seth et al., 1999</xref>), most probably because of the immune modulation and anti-inflammatory properties of chloroquine <italic>in vivo</italic> (<xref rid="bib4" ref-type="bibr">Connolly et al., 1988</xref>; <xref rid="bib14" ref-type="bibr">Katz and Russell, 2011</xref>; <xref rid="bib24" ref-type="bibr">Savarino et al., 2003</xref>). In a nonhuman primate model of CHIKV infection, chloroquine treatment was shown to exacerbate acute fever and delay the cellular immune response, leading to an incomplete viral clearance (<xref rid="bib23" ref-type="bibr">Roques et al., 2018</xref>). A clinical trial conducted during the chikungunya outbreak in 2006 in R&#x000e9;union Island showed that oral chloroquine treatment did not improve the course of the acute disease (<xref rid="bib6" ref-type="bibr">De Lamballerie et al., 2008</xref>) and that chronic arthralgia on day 300 post-illness was more frequent in treated patients than in the control group (<xref rid="bib23" ref-type="bibr">Roques et al., 2018</xref>). Altogether, the assessment of previous trials indicates that, to date, no acute virus infection has been successfully treated by chloroquine in humans.</p><p id="p0055">Chloroquine has also been tested in chronic viral diseases. Its use in the treatment of HIV-infected patients has been considered inconclusive (<xref rid="bib1" ref-type="bibr">Chauhan and Tikoo, 2015</xref>) and the drug has not been included in the panel recommended for HIV treatment. The only modest effect of chloroquine in the therapy of human virus infection was found for chronic hepatitis C: an increase of the early virological response to pegylated interferon plus ribavirin (<xref rid="bib12" ref-type="bibr">Helal et al., 2016</xref>) and, in a small sample size pilot trial in non-responder HCV patients, a transient viral load reduction (<xref rid="bib22" ref-type="bibr">Peymani et al., 2016</xref>) were observed. This was not enough to include chloroquine in the standardised therapeutic protocols for hepatitis C patients.</p><p id="p0060">Recently, Wang and colleagues (<xref rid="bib30" ref-type="bibr">Wang et al., 2020</xref>) evaluated <italic>in vitro</italic> five FDA-approved drugs and two broad spectrum antivirals against a clinical isolate of SARS-CoV-2. One of their conclusions was that "chloroquine (is) highly effective in the control of 2019-nCoV infection <italic>in vitro</italic>" and that its "safety track record suggests that it should be assessed in human patients suffering from the novel coronavirus disease". At least 16 different trials for SARS-CoV-2 already registered in the Chinese Clinical Trial Registry (ChiCTR2000029939, ChiCTR2000029935, ChiCTR2000029899, ChiCTR2000029898, ChiCTR2000029868, ChiCTR2000029837, ChiCTR2000029826, ChiCTR2000029803, ChiCTR2000029762, ChiCTR2000029761, ChiCTR2000029760, ChiCTR2000029741, ChiCTR2000029740, ChiCTR2000029609, ChiCTR2000029559, ChiCTR2000029542) propose to use chloroquine or hydroxychloroquine in the treatment of COVID-19 ("Chinese Clinical Trial Register" (<xref rid="bib2" ref-type="bibr">ChiCTR</xref>)). In a recent publication (<xref rid="bib11" ref-type="bibr">Gao et al., 2020</xref>), Gao and colleagues indicate that, "according to the news briefing", "results from more than 100 patients have demonstrated that chloroquine phosphate is superior to the control treatment in inhibiting the exacerbation of pneumonia, improving lung imaging findings, promoting a virus negative conversion, and shortening the disease course".</p><p id="p0065">This would represent the first successful use of chloroquine in humans for the treatment of an acute viral disease, and is undoubtedly excellent news, since this drug is cheap and widely available. However, it should be considered carefully before drawing definitive conclusions, since no data has been provided yet to support this announcement. Results were produced in ten different hospitals and possibly from a number of different clinical protocols among those listed above, which include various designs for control groups (none, different antivirals, placebo, etc.) and various outcome primary indicators. The final interpretation is therefore technically demanding, and in the absence of published data, it is difficult to reach any firm conclusion. It will be of the utmost importance to know if the observed efficacy is associated specifically with chloroquine phosphate, or if this includes other salts (e.g., sulfate) of chloroquine, and hydroxychloroquine. It is also necessary to determine if the benefit of chloroquine therapy depends on the age class, the clinical presentation or the stage of the disease.</p><p id="p0070">In conclusion, the option of using chloroquine in the treatment of SARS-CoV-2 should be examined with attention in light of the recent promising announcements, but also of the potential detrimental effect of the drug observed in previous attempts to treat acute viral diseases. We urge Chinese scientists to report the interim trial results currently running in China as soon as they are available. This should be preferentially done in a peer-reviewed publication with detailed information to allow the international scientific community to analyse the results, to confirm in prospective trials the efficacy of the proposed treatment and to guide future clinical practice.</p></body><back><ref-list id="cebib0010"><title>References</title><ref id="bib1"><element-citation publication-type="journal" id="sref1"><person-group person-group-type="author"><name><surname>Chauhan</surname><given-names>A.</given-names></name><name><surname>Tikoo</surname><given-names>A.</given-names></name></person-group><article-title>The enigma of the clandestine association between chloroquine and HIV-1 infection</article-title><source>HIV Med.</source><volume>16</volume><year>2015</year><fpage>585</fpage><lpage>590</lpage><pub-id pub-id-type="pmid">26238012</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="other" id="sref2"><person-group person-group-type="author"><name><surname>Chinese Clinical Trial Register (ChiCTR)</surname></name></person-group><article-title>The world health organization international clinical trials registered organization registered platform</article-title><comment>accessed 3.1.20</comment><ext-link ext-link-type="uri" xlink:href="http://www.chictr.org.cn/enIndex.aspx" id="intref0010">http://www.chictr.org.cn/enIndex.aspx</ext-link></element-citation></ref><ref id="bib3"><element-citation publication-type="journal" id="sref3"><person-group person-group-type="author"><name><surname>Colson</surname><given-names>P.</given-names></name><name><surname>Rolain</surname><given-names>J.-M.</given-names></name><name><surname>Raoult</surname><given-names>D.</given-names></name></person-group><article-title>Chloroquine for the 2019 novel coronavirus SARS-CoV-2</article-title><source>Int. J. Antimicrob. Agents</source><year>2020</year><comment>105923</comment></element-citation></ref><ref id="bib4"><element-citation publication-type="journal" id="sref4"><person-group person-group-type="author"><name><surname>Connolly</surname><given-names>K.M.</given-names></name><name><surname>Stecher</surname><given-names>V.J.</given-names></name><name><surname>Danis</surname><given-names>E.</given-names></name><name><surname>Pruden</surname><given-names>D.J.</given-names></name><name><surname>LaBrie</surname><given-names>T.</given-names></name></person-group><article-title>Alteration of interleukin-1 activity and the acute phase response in adjuvant arthritic rats treated with disease modifying antirheumatic drugs</article-title><source>Agents Actions</source><volume>25</volume><year>1988</year><fpage>94</fpage><lpage>105</lpage><pub-id pub-id-type="pmid">3142230</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal" id="sref5"><person-group person-group-type="author"><name><surname>Coombs</surname><given-names>K.</given-names></name><name><surname>Mann</surname><given-names>E.</given-names></name><name><surname>Edwards</surname><given-names>J.</given-names></name><name><surname>Brown</surname><given-names>D.T.</given-names></name></person-group><article-title>Effects of chloroquine and cytochalasin B on the infection of cells by Sindbis virus and vesicular stomatitis virus</article-title><source>J. Virol.</source><volume>37</volume><year>1981</year><fpage>1060</fpage><lpage>1065</lpage><pub-id pub-id-type="pmid">6262524</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal" id="sref6"><person-group person-group-type="author"><name><surname>De Lamballerie</surname><given-names>X.</given-names></name><name><surname>Boisson</surname><given-names>V.</given-names></name><name><surname>Reynier</surname><given-names>J.-C.</given-names></name><name><surname>Enault</surname><given-names>S.</given-names></name><name><surname>Charrel</surname><given-names>R.N.</given-names></name><name><surname>Flahault</surname><given-names>A.</given-names></name><name><surname>Roques</surname><given-names>P.</given-names></name><name><surname>Le Grand</surname><given-names>R.</given-names></name></person-group><article-title>On chikungunya acute infection and chloroquine treatment</article-title><source>Vector Borne Zoonotic</source><volume>8</volume><year>2008</year><fpage>837</fpage><lpage>839</lpage></element-citation></ref><ref id="bib7"><element-citation publication-type="journal" id="sref7"><person-group person-group-type="author"><name><surname>Delogu</surname><given-names>I.</given-names></name><name><surname>de Lamballerie</surname><given-names>X.</given-names></name></person-group><article-title>Chikungunya disease and chloroquine treatment</article-title><source>J. Med. Virol.</source><volume>83</volume><year>2011</year><fpage>1058</fpage><lpage>1059</lpage><pub-id pub-id-type="pmid">21503920</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal" id="sref8"><person-group person-group-type="author"><name><surname>Dowall</surname><given-names>S.D.</given-names></name><name><surname>Bosworth</surname><given-names>A.</given-names></name><name><surname>Watson</surname><given-names>R.</given-names></name><name><surname>Bewley</surname><given-names>K.</given-names></name><name><surname>Taylor</surname><given-names>I.</given-names></name><name><surname>Rayner</surname><given-names>E.</given-names></name><name><surname>Hunter</surname><given-names>L.</given-names></name><name><surname>Pearson</surname><given-names>G.</given-names></name><name><surname>Easterbrook</surname><given-names>L.</given-names></name><name><surname>Pitman</surname><given-names>J.</given-names></name><name><surname>Hewson</surname><given-names>R.</given-names></name><name><surname>Carroll</surname><given-names>M.W.</given-names></name></person-group><article-title>Chloroquine inhibited Ebola virus replication in vitro but failed to protect against infection and disease in the in vivo Guinea pig model</article-title><source>J. Gen. Virol.</source><volume>96</volume><year>2015</year><fpage>3484</fpage><lpage>3492</lpage><pub-id pub-id-type="pmid">26459826</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal" id="sref9"><person-group person-group-type="author"><name><surname>Falzarano</surname><given-names>D.</given-names></name><name><surname>Safronetz</surname><given-names>D.</given-names></name><name><surname>Prescott</surname><given-names>J.</given-names></name><name><surname>Marzi</surname><given-names>A.</given-names></name><name><surname>Feldmann</surname><given-names>F.</given-names></name><name><surname>Feldmann</surname><given-names>H.</given-names></name></person-group><article-title>Lack of protection against ebola virus from chloroquine in mice and hamsters</article-title><source>Emerg. Infect. Dis.</source><volume>21</volume><year>2015</year><fpage>1065</fpage><lpage>1067</lpage><pub-id pub-id-type="pmid">25988934</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal" id="sref10"><person-group person-group-type="author"><name><surname>Frisk-Holmberg</surname><given-names>M.</given-names></name><name><surname>Bergqvist</surname><given-names>Y.</given-names></name><name><surname>Englund</surname><given-names>U.</given-names></name></person-group><article-title>Chloroquine intoxication [letter]</article-title><source>Br. J. Clin. Pharmacol.</source><volume>15</volume><year>1983</year><fpage>502</fpage><lpage>503</lpage><pub-id pub-id-type="pmid">6849790</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal" id="sref11"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>J.</given-names></name><name><surname>Tian</surname><given-names>Z.</given-names></name><name><surname>Yang</surname><given-names>X.</given-names></name></person-group><article-title>Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies</article-title><source>Biosci. Trends</source><year>2020</year></element-citation></ref><ref id="bib12"><element-citation publication-type="journal" id="sref12"><person-group person-group-type="author"><name><surname>Helal</surname><given-names>G.K.</given-names></name><name><surname>Gad</surname><given-names>M.A.</given-names></name><name><surname>Abd-Ellah</surname><given-names>M.F.</given-names></name><name><surname>Eid</surname><given-names>M.S.</given-names></name></person-group><article-title>Hydroxychloroquine augments early virological response to pegylated interferon plus ribavirin in genotype-4 chronic hepatitis C patients</article-title><source>J. Med. Virol.</source><volume>88</volume><year>2016</year><fpage>2170</fpage><lpage>2178</lpage><pub-id pub-id-type="pmid">27183377</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal" id="sref13"><person-group person-group-type="author"><name><surname>Inglot</surname><given-names>A.D.</given-names></name></person-group><article-title>Comparison of the antiviral activity in vitro of some non-steroidal anti-inflammatory drugs</article-title><source>J. Gen. Virol.</source><volume>4</volume><year>1969</year><fpage>203</fpage><lpage>214</lpage><pub-id pub-id-type="pmid">4306296</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal" id="sref14"><person-group person-group-type="author"><name><surname>Katz</surname><given-names>S.J.</given-names></name><name><surname>Russell</surname><given-names>A.S.</given-names></name></person-group><article-title>Re-evaluation of antimalarials in treating rheumatic diseases: re-appreciation and insights into new mechanisms of action</article-title><source>Curr. Opin. Rheumatol.</source><volume>23</volume><year>2011</year><fpage>278</fpage><lpage>281</lpage><pub-id pub-id-type="pmid">21448012</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal" id="sref15"><person-group person-group-type="author"><name><surname>Keyaerts</surname><given-names>E.</given-names></name><name><surname>Li</surname><given-names>S.</given-names></name><name><surname>Vijgen</surname><given-names>L.</given-names></name><name><surname>Rysman</surname><given-names>E.</given-names></name><name><surname>Verbeeck</surname><given-names>J.</given-names></name><name><surname>Van Ranst</surname><given-names>M.</given-names></name><name><surname>Maes</surname><given-names>P.</given-names></name></person-group><article-title>Antiviral activity of chloroquine against human coronavirus OC43 infection in newborn mice</article-title><source>Antimicrob. Agents Chemother.</source><volume>53</volume><year>2009</year><fpage>3416</fpage><lpage>3421</lpage><pub-id pub-id-type="pmid">19506054</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal" id="sref16"><person-group person-group-type="author"><name><surname>Keyaerts</surname><given-names>E.</given-names></name><name><surname>Vijgen</surname><given-names>L.</given-names></name><name><surname>Maes</surname><given-names>P.</given-names></name><name><surname>Neyts</surname><given-names>J.</given-names></name><name><surname>Ranst</surname><given-names>M.V.</given-names></name></person-group><article-title>In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine</article-title><source>Biochem. Biophys. Res. Commun.</source><volume>323</volume><year>2004</year><fpage>264</fpage><lpage>268</lpage><pub-id pub-id-type="pmid">15351731</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal" id="sref17"><person-group person-group-type="author"><name><surname>Li</surname><given-names>C.</given-names></name><name><surname>Zhu</surname><given-names>X.</given-names></name><name><surname>Ji</surname><given-names>X.</given-names></name><name><surname>Quanquin</surname><given-names>N.</given-names></name><name><surname>Deng</surname><given-names>Y.-Q.</given-names></name><name><surname>Tian</surname><given-names>M.</given-names></name><name><surname>Aliyari</surname><given-names>R.</given-names></name><name><surname>Zuo</surname><given-names>X.</given-names></name><name><surname>Yuan</surname><given-names>L.</given-names></name><name><surname>Afridi</surname><given-names>S.K.</given-names></name><name><surname>Li</surname><given-names>X.-F.</given-names></name><name><surname>Jung</surname><given-names>J.U.</given-names></name><name><surname>Nielsen-Saines</surname><given-names>K.</given-names></name><name><surname>Qin</surname><given-names>F.X.-F.</given-names></name><name><surname>Qin</surname><given-names>C.-F.</given-names></name><name><surname>Xu</surname><given-names>Z.</given-names></name><name><surname>Cheng</surname><given-names>G.</given-names></name></person-group><article-title>Chloroquine, a FDA-approved drug, prevents Zika virus infection and its associated congenital microcephaly in mice</article-title><source>EBioMedicine</source><volume>24</volume><year>2017</year><fpage>189</fpage><lpage>194</lpage><pub-id pub-id-type="pmid">29033372</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal" id="sref18"><person-group person-group-type="author"><name><surname>Maheshwari</surname><given-names>R.K.</given-names></name><name><surname>Srikantan</surname><given-names>V.</given-names></name><name><surname>Bhartiya</surname><given-names>D.</given-names></name></person-group><article-title>Chloroquine enhances replication of Semliki Forest virus and encephalomyocarditis virus in mice</article-title><source>J. Virol.</source><volume>65</volume><year>1991</year><fpage>992</fpage><lpage>995</lpage><pub-id pub-id-type="pmid">1846212</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal" id="sref19"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>D.K.</given-names></name><name><surname>Lenard</surname><given-names>J.</given-names></name></person-group><article-title>Antihistaminics, local anesthetics, and other amines as antiviral agents</article-title><source>Proc. Natl. Acad. Sci. U.S.A.</source><volume>78</volume><year>1981</year><fpage>3605</fpage><lpage>3609</lpage><pub-id pub-id-type="pmid">6115382</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal" id="sref20"><person-group person-group-type="author"><name><surname>Pallister</surname><given-names>J.</given-names></name><name><surname>Middleton</surname><given-names>D.</given-names></name><name><surname>Crameri</surname><given-names>G.</given-names></name><name><surname>Yamada</surname><given-names>M.</given-names></name><name><surname>Klein</surname><given-names>R.</given-names></name><name><surname>Hancock</surname><given-names>T.J.</given-names></name><name><surname>Foord</surname><given-names>A.</given-names></name><name><surname>Shiell</surname><given-names>B.</given-names></name><name><surname>Michalski</surname><given-names>W.</given-names></name><name><surname>Broder</surname><given-names>C.C.</given-names></name><name><surname>Wang</surname><given-names>L.-F.</given-names></name></person-group><article-title>Chloroquine administration does not prevent Nipah virus infection and disease in ferrets</article-title><source>J. Virol.</source><volume>83</volume><year>2009</year><fpage>11979</fpage><lpage>11982</lpage><pub-id pub-id-type="pmid">19759137</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal" id="sref21"><person-group person-group-type="author"><name><surname>Paton</surname><given-names>N.I.</given-names></name><name><surname>Lee</surname><given-names>L.</given-names></name><name><surname>Xu</surname><given-names>Y.</given-names></name><name><surname>Ooi</surname><given-names>E.E.</given-names></name><name><surname>Cheung</surname><given-names>Y.B.</given-names></name><name><surname>Archuleta</surname><given-names>S.</given-names></name><name><surname>Wong</surname><given-names>G.</given-names></name><name><surname>Wilder-Smith</surname><given-names>A.</given-names></name><name><surname>Smith</surname><given-names>A.W.</given-names></name></person-group><article-title>Chloroquine for influenza prevention: a randomised, double-blind, placebo controlled trial</article-title><source>Lancet Infect. Dis.</source><volume>11</volume><year>2011</year><fpage>677</fpage><lpage>683</lpage><pub-id pub-id-type="pmid">21550310</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal" id="sref22"><person-group person-group-type="author"><name><surname>Peymani</surname><given-names>P.</given-names></name><name><surname>Yeganeh</surname><given-names>B.</given-names></name><name><surname>Sabour</surname><given-names>S.</given-names></name><name><surname>Geramizadeh</surname><given-names>B.</given-names></name><name><surname>Fattahi</surname><given-names>M.R.</given-names></name><name><surname>Keyvani</surname><given-names>H.</given-names></name><name><surname>Azarpira</surname><given-names>N.</given-names></name><name><surname>Coombs</surname><given-names>K.M.</given-names></name><name><surname>Ghavami</surname><given-names>S.</given-names></name><name><surname>Lankarani</surname><given-names>K.B.</given-names></name></person-group><article-title>New use of an old drug: chloroquine reduces viral and ALT levels in HCV non-responders (a randomized, triple-blind, placebo-controlled pilot trial)</article-title><source>Can. J. Physiol. Pharmacol.</source><volume>94</volume><year>2016</year><fpage>613</fpage><lpage>619</lpage><pub-id pub-id-type="pmid">26998724</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal" id="sref23"><person-group person-group-type="author"><name><surname>Roques</surname><given-names>P.</given-names></name><name><surname>Thiberville</surname><given-names>S.-D.</given-names></name><name><surname>Dupuis-Maguiraga</surname><given-names>L.</given-names></name><name><surname>Lum</surname><given-names>F.-M.</given-names></name><name><surname>Labadie</surname><given-names>K.</given-names></name><name><surname>Martinon</surname><given-names>F.</given-names></name><name><surname>Gras</surname><given-names>G.</given-names></name><name><surname>Lebon</surname><given-names>P.</given-names></name><name><surname>Ng</surname><given-names>L.F.P.</given-names></name><name><surname>de Lamballerie</surname><given-names>X.</given-names></name><name><surname>Le Grand</surname><given-names>R.</given-names></name></person-group><article-title>Paradoxical effect of chloroquine treatment in enhancing chikungunya virus infection</article-title><source>Viruses</source><volume>10</volume><year>2018</year></element-citation></ref><ref id="bib24"><element-citation publication-type="journal" id="sref24"><person-group person-group-type="author"><name><surname>Savarino</surname><given-names>A.</given-names></name><name><surname>Boelaert</surname><given-names>J.R.</given-names></name><name><surname>Cassone</surname><given-names>A.</given-names></name><name><surname>Majori</surname><given-names>G.</given-names></name><name><surname>Cauda</surname><given-names>R.</given-names></name></person-group><article-title>Effects of chloroquine on viral infections: an old drug against today's diseases</article-title><source>Lancet Infect. Dis.</source><volume>3</volume><year>2003</year><fpage>722</fpage><lpage>727</lpage><pub-id pub-id-type="pmid">14592603</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal" id="sref25"><person-group person-group-type="author"><name><surname>Seth</surname><given-names>P.</given-names></name><name><surname>Mani</surname><given-names>H.</given-names></name><name><surname>Singh</surname><given-names>A.K.</given-names></name><name><surname>Banaudha</surname><given-names>K.K.</given-names></name><name><surname>Madhavan</surname><given-names>S.</given-names></name><name><surname>Sidhu</surname><given-names>G.S.</given-names></name><name><surname>Gaddipati</surname><given-names>J.P.</given-names></name><name><surname>Vogel</surname><given-names>S.N.</given-names></name><name><surname>Maheshwari</surname><given-names>R.K.</given-names></name></person-group><article-title>Acceleration of viral replication and up-regulation of cytokine levels by antimalarials: implications in malaria-endemic areas</article-title><source>Am. J. Trop. Med. Hyg.</source><volume>61</volume><year>1999</year><fpage>180</fpage><lpage>186</lpage><pub-id pub-id-type="pmid">10463664</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal" id="sref26"><person-group person-group-type="author"><name><surname>Shimizu</surname><given-names>Y.</given-names></name><name><surname>Yamamoto</surname><given-names>S.</given-names></name><name><surname>Homma</surname><given-names>M.</given-names></name><name><surname>Ishida</surname><given-names>N.</given-names></name></person-group><article-title>Effect of chloroquine on the growth of animal viruses</article-title><source>Arch. Gesamte Virusforsch.</source><volume>36</volume><year>1972</year><fpage>93</fpage><lpage>104</lpage><pub-id pub-id-type="pmid">4335025</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal" id="sref27"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>Y.W.</given-names></name><name><surname>Yam</surname><given-names>W.K.</given-names></name><name><surname>Sun</surname><given-names>J.</given-names></name><name><surname>Chu</surname><given-names>J.J.H.</given-names></name></person-group><article-title>An evaluation of chloroquine as a broad-acting antiviral against hand, foot and mouth disease</article-title><source>Antivir. Res.</source><volume>149</volume><year>2018</year><fpage>143</fpage><lpage>149</lpage><pub-id pub-id-type="pmid">29175128</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal" id="sref28"><person-group person-group-type="author"><name><surname>Tricou</surname><given-names>V.</given-names></name><name><surname>Minh</surname><given-names>N.N.</given-names></name><name><surname>Van</surname><given-names>T.P.</given-names></name><name><surname>Lee</surname><given-names>S.J.</given-names></name><name><surname>Farrar</surname><given-names>J.</given-names></name><name><surname>Wills</surname><given-names>B.</given-names></name><name><surname>Tran</surname><given-names>H.T.</given-names></name><name><surname>Simmons</surname><given-names>C.P.</given-names></name></person-group><article-title>A randomized controlled trial of chloroquine for the treatment of dengue in Vietnamese adults</article-title><source>PLoS Neglected Trop. Dis.</source><volume>4</volume><year>2010</year><fpage>e785</fpage></element-citation></ref><ref id="bib29"><element-citation publication-type="journal" id="sref29"><person-group person-group-type="author"><name><surname>Vigerust</surname><given-names>D.J.</given-names></name><name><surname>McCullers</surname><given-names>J.A.</given-names></name></person-group><article-title>Chloroquine is effective against influenza A virus in vitro but not in vivo. Influenza Other Respir</article-title><source>Viruses</source><volume>1</volume><year>2007</year><fpage>189</fpage><lpage>192</lpage></element-citation></ref><ref id="bib30"><element-citation publication-type="journal" id="sref30"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>M.</given-names></name><name><surname>Cao</surname><given-names>R.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Yang</surname><given-names>X.</given-names></name><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Xu</surname><given-names>M.</given-names></name><name><surname>Shi</surname><given-names>Z.</given-names></name><name><surname>Hu</surname><given-names>Z.</given-names></name><name><surname>Zhong</surname><given-names>W.</given-names></name><name><surname>Xiao</surname><given-names>G.</given-names></name></person-group><article-title>Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro</article-title><source>Cell Res.</source><year>2020</year><fpage>1</fpage><lpage>3</lpage><pub-id pub-id-type="pmid">31802008</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal" id="sref31"><person-group person-group-type="author"><name><surname>Yan</surname><given-names>Y.</given-names></name><name><surname>Zou</surname><given-names>Z.</given-names></name><name><surname>Sun</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Xu</surname><given-names>K.-F.</given-names></name><name><surname>Wei</surname><given-names>Y.</given-names></name><name><surname>Jin</surname><given-names>N.</given-names></name><name><surname>Jiang</surname><given-names>C.</given-names></name></person-group><article-title>Anti-malaria drug chloroquine is highly effective in treating avian influenza A H5N1 virus infection in an animal model</article-title><source>Cell Res.</source><volume>23</volume><year>2013</year><fpage>300</fpage><lpage>302</lpage><pub-id pub-id-type="pmid">23208422</pub-id></element-citation></ref></ref-list></back></article>